Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EPS (Basic) (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed EPS (Basic) for 16 consecutive years, with -$0.09 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 35.71% to -$0.09 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.19 through Dec 2025, up 59.57% year-over-year, with the annual reading at -$0.19 for FY2025, 58.7% up from the prior year.
  • EPS (Basic) hit -$0.09 in Q4 2025 for Cumberland Pharmaceuticals, up from -$0.13 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.08 in Q2 2021 to a low of -$0.44 in Q4 2023.
  • Historically, EPS (Basic) has averaged -$0.09 across 5 years, with a median of -$0.08 in 2024.
  • Biggest five-year swings in EPS (Basic): surged 233.33% in 2021 and later crashed 1500.0% in 2024.
  • Year by year, EPS (Basic) stood at -$0.26 in 2021, then skyrocketed by 34.62% to -$0.17 in 2022, then plummeted by 158.82% to -$0.44 in 2023, then soared by 68.18% to -$0.14 in 2024, then surged by 35.71% to -$0.09 in 2025.
  • Business Quant data shows EPS (Basic) for CPIX at -$0.09 in Q4 2025, -$0.13 in Q3 2025, and -$0.05 in Q2 2025.